Gsa Capital Partners LLP Collegium Pharmaceutical, Inc Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$10.7 - $22.24 $252,423 - $524,663	-23,591 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$10.16 - $13.28 $489,823 - $640,242	-48,211 Reduced 67.14%	23,591 $271,000
Q2 2019 Aug 06, 2019	BUY	$10.62 - $16.59 $77,664 - $121,322	7,313 Added 11.34%	71,802 $944,000
Q1 2019 May 15, 2019	SELL	$13.58 - $18.72 $26,453 - $36,466	-1,948 Reduced 2.93%	64,489 $976,000
Q4 2018 Feb 12, 2019	SELL	$14.78 - $19.68 $154,643 - $205,911	-10,463 Reduced 13.61%	66,437 $1.14 Million
Q3 2018 Nov 13, 2018	BUY	$14.16 - $24.3 $471,528 - $809,190	33,300 Added 76.38%	76,900 $1.13 Million
Q2 2018 Aug 09, 2018	BUY	$21.79 - $28.29 $950,044 - $1.23 Million	43,600 New	43,600 $1.04 Million

249

36.2M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.11B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.